A randomized crossover trial of micro-encapsulated aspirin (Levius) and aloxiprin (Palaprin Forte) was carried out on thirty-three hospital out-patients with rheumatoid arthritis. Both preparations improved the clinical status of the patients. The difference in response to the two preparations was not significant, except for effect on functional status where the micro-encapsulated aspirin was found to be significantly better at the 5% level. Apart from six complaints of constipation with aloxiprin compared with only one with Levius, the side-effects were similar. The trial has shown that Levius can be conveniently given in divided doses thrice daily without loss of efficacy.
Get full access to this article
View all access options for this article.
References
1.
CroftD NCuddiganJ PH Sweetlord Carole (1972) Gastric Bleeding and Benorylate, a New Aspirin. British Medical Journal3, 545
2.
GellerJ (1968) A Comparative Trial of Aloxiprin (Palaprin Forte) and Phenylbutazone (Butazolidin). The British Journal of Clinical Practice22, 9, 392
3.
RopesM WBennettG ACobbSJacobRJessarR A (1959) Revision of Diagnostic Criteria for Rheumatoid Arthritis. Annals of the Rheumatic Diseases18, 49
4.
ValerieSaggers HChausseaudL FCooperA J (1972) Plasma Concentrations, Duration of Analgesia and Bio-Availability of Micro-Encapsulated Aspirin (Levius). Clinical Trials Journal (London) 9, 3, 36
5.
WoodP HNHarvey-SmithE ADixonAStJ (1962) Salicylates and Gastrointestinal Bleeding: Acetylsalicylic Acid and Aspirin Derivatives. British Medical Journal1, 669
